SeeThruEquity Initiates Research Coverage on NanoViricides, Inc.

Business Wire


SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on NanoViricides, Inc. (NNVC), a development stage company that is creating special purpose nanomaterials for viral therapy.

“Unlike a typical emerging biotechnology company with one, or maybe two, lead drug candidates with blockbuster market potential, NanoViricides can use their technology to target numerous drug categories. They are initially developing Injectable FluCide™ for hospitalized patients being treated for all influenzas. This represents a $25bn annual market opportunity,” remarked Ajay Tandon, CEO of SeeThruEquity. “We are initiating coverage with a fair value estimate of $7.21 per share.”

The note is available to SeeThruEquity Select Members on SeeThruEquity's website and can be directly accessed here: NNVC Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The note will also be available on these platforms.

Please review important disclosures on our website at

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit

About NanoViricides, Inc.

NanoViricides is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. For more information, please go to

Ajay Tandon, 646-495-0939

View Comments (0)